论文部分内容阅读
正如大多数疾病的情况一样,在麻疯病方面所取得的进展不是很快而是很慢。如果以习惯为例,则氨苯砜(Dapson)或氯苯吩嗪(Clofazimine)的单一疗法,仍然广泛地用于治疗麻疯病,且通常奏效。由于含菌少的(不确定的、结核节样的以及边界的-结核节样的)患者需要治疗3～7年,而多种杆菌的(中央的-边界的、边界的-麻疯结节的和麻疯结节的)病人需要终身治疗,故病人的顺应性依然是一个难题。由于原发性和继发性氨苯砜耐药性已经发生,复发也就成为常见而严重的问题,因此,不可能再推荐单一疗法。希望使用利福平的多种药物疗法来缩短
As in most diseases, the progress made in leprosy is not fast but slow. If used as an example, monotherapy with Dapsone or Clofazimine is still widely used to treat leprosy and is usually effective. Because fewer bacteria (indefinite, tubercle-like and border-tuberodular) patients require treatment for 3 to 7 years, while multiple bacilli (central-border, border-leprous nodules And leprosy nodules) patients require lifelong treatment, so the patient’s compliance is still a problem. Since primary and secondary dapsone resistance has already occurred, recurrences are a common and serious problem, so it is not possible to recommend monotherapy again. I hope to use a variety of rifampicin to shorten the medication